BristolMyers Squibb Co. (BMY) Stock Quote

Detailed Quote for BristolMyers Squibb Co. (BMY)

After Hours: $ 31.8368

-0.0632 (-0.20%)

Volume: 396.82 k

5:49 PM EST Feb 10, 2012

close 52 Week Information

52 Week High

January 3, 2012

Close: 35.44

52 Week Low

March 16, 2011

Close: 24.97

Today

Last Price
31.90

Change $
0.09

Change %
0.28%

Tick
N/A

Bid
31.75

Bid Size
200

Ask
31.96

Ask Size
100

Open
31.75

High
31.94

Low
31.65

Prev Close
31.99

Last Trade
2/10/12

Volume
8.09 m

52 Wk Hi
35.44

52 Wk Low
24.97

Market Cap
54.06 b

Ex-Div Date
1/4/12

Div Rate
1.36

Yield
4.2633

Shares
1,694,531,520

EPS (TTM)
2.16

PE Ratio
14.80

close Exchange Information Listed On New York Stock Exchange (NYE) Exchange
NYE

News and Media for BristolMyers Squibb Co. (BMY)

Sector News | Topic News

News for BMY

Wed, Feb 08, 2012

3:19 PM

Bristol-Myers Squibb to Present at Leerink Swann 2012 Global Healthcare Conference - Business Wire

1:30 AM

Sanofi and Bristol-Myers Squibb Collect Damages in Plavix Patent Litigation with Apotex - Business Wire

Tue, Feb 07, 2012

7:00 AM

First and only treatment to extend survival for people with metastatic melanoma, the most deadly form of skin cancer, approved in Canada - Canada Newswire

Fri, Feb 03, 2012

7:30 AM

Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Inhibitex, Inc. - Business Wire

Thu, Jan 26, 2012

7:30 AM

Bristol-Myers Squibb Delivers Solid Fourth Quarter Capping a Year Highlighted by New Product Approvals, Continued Execution of Strategic Transactions and Good Operating Performance - Business Wire

Tue, Jan 24, 2012

10:07 AM

Bristol-Myers Squibb Names Gerald L. Storch to Board of Directors - Business Wire

Fri, Jan 20, 2012

9:00 AM

A Forward Look, the Year Ahead - Featured Research on Convergys Corporation and Bristol Myers Squibb Co. - Marketwire

Thu, Jan 19, 2012

8:30 AM

Bristol-Myers Squibb Announces Charitable Donation of $6.9 Million to Support Cancer Patients - Business Wire

2:00 AM

Bristol-Myers Squibb and AstraZeneca Receive Complete Response Letter from U.S. Food and Drug Administration for Dapagliflozin - Business Wire

Wed, Jan 18, 2012

5:01 PM

First Hepatitis C Treatment Data Demonstrating Proof of Principle with Direct-Acting Antiviral-only Therapy Published - Business Wire

Fri, Jan 13, 2012

2:08 PM

The Law Firm of Levi & Korsinsky, LLP Notifies Investors of Claims of Breaches of Fiduciary Duty by the Board of Inhibitex, Inc. in Connection With the Sale of the Company to Bristol-Myers Squibb Co. - Marketwire

7:30 AM

Bristol-Myers Squibb Begins Tender Offer to Acquire Inhibitex, Inc. - Business Wire

Sat, Jan 07, 2012

9:13 PM

Bristol-Myers Squibb to Acquire Inhibitex - Business Wire

Thu, Jan 05, 2012

2:00 PM

Bristol-Myers Squibb to Announce Results for Fourth Quarter, Full Year 2011 on January 26 - Business Wire

Wed, Jan 04, 2012

10:30 AM

Bristol-Myers Squibb to Present at J.P. Morgan Healthcare Conference - Business Wire

Thu, Dec 29, 2011

2:13 PM

Bristol-Myers Squibb to Present at Goldman Sachs Healthcare CEOs Unscripted Conference - Business Wire

Thu, Dec 22, 2011

4:30 PM

BRISK-PS Study with Investigational Compound Brivanib in Hepatocellular Carcinoma Completed - Business Wire

1:00 PM

Bristol-Myers Squibb and the Gladstone Institutes Enter Three-Year Discovery Partnership in Alzheimer's Disease - Business Wire

Fri, Dec 16, 2011

7:00 AM

Health Canada Approves Abilify® as First Atypical Antipsychotic in the Treatment of Adolescents with Schizophrenia - Canada Newswire

Tue, Dec 13, 2011

7:28 PM

Simcere and Bristol-Myers Squibb Enter Innovative Partnership to Develop Cardiovascular Compound - PR Newswire

More News for BMY >>

Tags for BristolMyers Squibb Co.